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Abstract
The recent introduction of fluorescent bead-based technology, allowing the measurement of multiples analytes in a single
25–50 ml sample has revolutionized the study of cytokine responses. However, such multiplex approaches may compromise
the ability of these assays to accurately measure actual cytokine levels. This study evaluates the performance of three
commercially available multiplex cytokine fluorescent bead-based immunoassays (Bio-Rad’s Cytokine 17-plex kit; LINCO
Inc’s 29-plex kit; and RnD System’s Fluorokine-Multi Analyte Profiling (MAP) base kit A and B). The LINCO Inc kit was found to
be the most sensitive assay for measuring concentrations of multiple recombinant cytokines in samples that had been
spiked with serial dilutions of the standard provided by the manufacturer, followed respectively by the RnD Fluorokine-
(MAP) and Bio-Rad 17-plex kits. A positive correlation was found in the levels of IFN-c measured in antigen stimulated whole
blood culture supernatants by the LINCO Inc 29-plex, RnD Fluorokine-(MAP) and RnD system IFN-c Quantikine ELISA kits
across a panel of controls and stimulated samples. Researchers should take the limitation of such multiplexed assays into
account when planning experiments and the most appropriate use for these tests may currently be as screening tools for
the selection of promising markers for analysis by more sensitive techniques.
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Introduction
Cytokines are important modulators of immune response
pathways [7,18,19]. Cytokine expression profiling (CEP) has
become a popular and established method for the identification
and characterisation of disease-associated immune responses
[4,6,8,9]. Previously, CEP was a laborious process requiring
substantial sample volumes when multiple cytokines were under
investigation. However, CEP methodology has been revolution-
ised by the recent introduction of fluorescent bead-based luminex
technology, a capture/detection sandwich type immunoassay
allowing the measurement of up to 100 different analytes in a
single 50 ml sample [16].
The reduced sample volume and time-saving advantages of the
luminex system have made it an attractive method for large-scale
cross-sectional, association or cohort studies which investigate the
host immune response [1,13,15,16]. Khan et al. [11] have
comparatively assessed multiplex kits from LINCO Research, Bio-
Rad Laboratories, RnD Systems and Biosource International and
compared them to an enzyme-linked immunosorbant assay (ELISA).
The comparison was based on the measurement of a sample of five
cytokines (serum samples from healthy individuals intravenously
injected with endotoxin). They reported that the cytokine concen-
trations, as measured by the different kits, showed similar trends,
although the absolute concentrations measured were different.
There are also a number of reports validating luminex systems.
These studies often used kits with a narrow panel of cytokines. The
present study not only has the advantage of combining a head-to-
head comparison of different kits and assays on their ability to
measure cytokine levels in blood samples, but is also the first
independent study to comparatively assess the recovery of each
cytokine by the commercially available Bio-Rad 17-plex, LINCO
29-plex and RnD Fluorokine-(MAP) base kits A and B (13
cytokines total) with reference to instrument settings and
calibration.
Methods
Study design
This study followed an integrated methodology, comparing 3
commercially available multi-plex luminex kits (Cytokine 17-plex
kit by Bio-Rad; a 29-plex kit by LINCO Research; and
Fluorokine-Multi Analytes Profiling (MAP) kit) by RnD System
as well as the RnD Systems IFN-c Quantikine ELISA kit. We have
used the following two approaches: 1) Measurement of recombi-
nant cytokines in serum and in unstimulated diluted whole blood
culture supernatant samples, each spiked with serial dilutions of
the multiplex standard provided by the luminex kit manufacturer
in order to calculate the recovery (accuracy) of the assay for each
of the different cytokines; 2) Measurement of native, induced IFN-
PLoS ONE | www.plosone.org 1 July 2008 | Volume 3 | Issue 7 | e2535c, in vitro, whole blood culture supernatants where, whole blood
culture supernatants were stimulated with Mycobacterium tuberculosis
(Mtb) antigens or Bacille Calmette Guerin (BCG).
Definitions
Recovery. Ratio of the observed amount of cytokine
compared to the expected known amount of cytokine in a
sample, expressed as a percentage. An acceptable recovery falls
within the range of 70–130% (Bio-Rad Principles of Curve Fitting for
Multiplex Sandwich Immunoassays, Rev B).
The following formula was used to calculate recovery:
Observed Concentration in spiked sample{Observed Concentration in unspiked sample ð Þ|100
Expected concentration amount of recombinant cytokine used to spike sample ðÞ
The definition and calculations of recovery were obtained from
the RnD-Systems spike and recovery immunoassay sample
validation protocol.
Reading. Reported fluorescence of the sample
Positive reading. Reported fluorescence of a sample that is
above background fluorescence and corresponds to a positive
concentration.
RP1. RP1 represents the fluorescence channel used for assay
quantification. Low RP1 is the fluorescent channel recommended
for quantification of a wide range of cytokines with a wide
dynamic range of concentrations; whereas high RP1 is
recommended for quantification of low concentrations of
cytokines as it provides greater sensitivity.
5 PL-(parameters logistic) Regression Curve. A standard
curve build upon a five parameters logistic equation and that
corrects for asymmetry in the curve shape.
Manufacturer 1. Bio-Rad
Manufacturer 2. LINCO Research
Manufacturer 3. RnD Systems
Manufacture 1 assay
Experiment 1. The Bio-Rad human cytokine 17-plex assay
was carried out according to the manufacturer’s instructions, with
a few exceptions as stipulated below. Briefly, a nine-point standard
curve was generated by performing serial dilutions of the
reconstituted normalised standard (lot # 5004060). This was not
reconstituted with standard diluent, but rather with unstimulated
whole blood assay supernatant, which was prepared by diluting
whole blood one in ten with RPMI-1640 (GIBCO) and incubating
at 37uC, 5% CO2 for six days. This was done in order to ensure
that the matrix used in the generation of the standard curve
resembled that of the samples as closely as possible as preliminary
test showed that this method was superior to dilution of standards
in standard diluent (data not shown). In order to assess recovery,
supernatant samples SN1, SN2 and SN3 were each spiked at three
concentrations (ranging from 7–5461 pg/ml) with recombinant
cytokine using the Bio-plex kit standard. The assays were run in
duplicate, which produced in total six concentration replicates. In
order to keep the matrix of the spiked samples as similar as
possible to the matrix of the standard curve, the volume of
reconstituted standard used to spike the samples in all experiments
was kept to a minimum and never exceeded 10 ml. A 50 ml volume
of each sample, control or standard was added to a 96 well plate
(provided with the kit) containing 50 ml of antibody coated
fluorescent beads. Biotinylated secondary and streptavidin-PE
antibodies were added to the plate with alternate incubation and
washing steps. After the last wash step, 125 ml of wash buffer was
added to the wells, the plate incubated and read on the Bio-plex
array reader, using a 5 PL regression curve to plot the standard
curve. Samples and controls were read at both a low RP1 target
setting (used to maximize assay sensitivity when the expected
concentrations are below 3 200 pg/ml) and a high RP1 target
setting (used for broad range concentrations) on the Bio-plex
suspension array using a high throughput fluidics (HTF) system
(cat# 171000005). Data was subsequently analysed using the Bio-
plex manager software, version 3.
Experiment 2. The standard curve was generated and the
assay conducted as described above in the section on the Bio-Rad
human 17-plex assay experiment 1. Two sets of samples were used. The
first set was generated using whole blood from a healthy laboratory
donor diluted one in ten with RPMI-1640 with glutamax and
stimulated with different Mtb antigens, (generously donated by
Tom Ottenhoff, Leiden University), and a phytohaemagglutinin
(PHA)-stimulated positive control. Unstimulated culture
supernatant served as a negative control. The second set of
samples was generated from unstimulated whole blood culture as
described above. Supernatants were harvested on day seven and
spiked at five different concentrations with recombinant cytokine
from the Bio-Rad standard (lot # 5004060. The six concentrations
at which samples were spiked were unique for each cytokine with
the lowest spike ranging from 2–43 pg/ml and the highest from
1191–8062 pg/ml). The results of these tests were used to
calculate recovery.
Manufacturer 2 assay
Experiment 1. A human 29-plex LINCO assay (cat no
HCYTO -60-K-PMX29) was done according to manufacturer’s
instructions. Briefly, a standard curve ranging from 3.2 pg/ml to 10
000 pg/ml was generated by serial dilution of reconstituted
standard. Two sets of samples were used, as described earlier,
with the exception that for the second set of samples the LINCO
Research standard (provided with the kit) was used to spike
unstimulated whole blood culture at final concentrations of 5000,
1000, 500, 50 and 10 pg/ml. Additionally for the assessment of the
LINCOkit reproducibilityfivealiquots ofthesame PHA-stimulated
whole blood supernatant were produced and each aliquot was run
infivedifferentexperimentsondifferentdays.Brieflythefilterplates
wereblockedbypipetting200 mlofassaybufferintoeachwell.After
10 minutes the assay buffer was discarded by vacuum aspiration
and 25 ml of assay diluent was added to the wells designated for the
samples, while 25 ml of RPMI-1640 with glutamax (GIBCO) was
added to the wells designated for standards. According to the plate
layout, 25 ml of either standard or sample was then added to the
appropriate wells after which 25 ml of antibody coated fluorescent
beads was added. Biotinylated secondary (detection) and
Streptavidin-PE-labelled antibodies were then added to the plate
respectively, with alternate incubation and washing steps. Finally
100 ml of sheath fluid was added to the wells and the plate read
immediately on the Bio-plex array reader, at high and low RP1
targets, using a 5 PL regression curve.
Experiment 2. A repeat of the experiment 1 was done by
measuring 21 cytokines in two sets of samples including 171 Mtb
antigens stimulated culture supernatant and spiked unstimulated
whole blood culture (as previously described). Only this time
samples were spiked at 2 different concentrations. The Plate was
read at low RP1 targets as previously described.
Manufacturer 3 assay
Experiment 1. The assay was done according to the
manufacturer’s instructions. Briefly, the standard curves for the
RnD System fluorokine-(MAP) human base kits A (cat #
LUH000) and B (cat # LUH001) were generated by
reconstitution of standards in standard diluent provided with the
Luminex Immunoassays
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blood culture supernatants used for the Bio-plex experiment 2 and
LINCO 29-plex assays described earlier, as well as serum (diluted
one in four) and whole blood supernatant spiked at six different
concentrations with recombinant cytokine from the RnD System’s
standard (Part # 895531, lot # 238222 and Part # 895546, lot #
238223 [base kit A] and Part # 892794, lot # 233020 [base kit
B]). The six concentrations at which samples were spiked were
unique for each cytokine with the lowest spike ranging from 14–
600 pg/ml and the highest from 950–19 000 pg/ml. An eight-
point standard curve, with each cytokine spanning its own unique
specific range, was generated and 50 ml of each standard and
sample were added to a 96-well plate containing fluorescent
antibody coated beads. After alternate incubation and washing
steps, detection and PE-labelled secondary antibodies were added
and the plate read on the Bio-plex array reader, at a low RP1
target, using a 5 PL regression curve.
Experiment 2. The assay was done according to the
manufacturer’s instructions. Serum (diluted one in four) and
whole blood culture supernatant were spiked with seven different
concentrations (ranging from 5–1700 pg/ml) of recombinant
cytokine from the RnD System’s standard and measured as
previously described.
RnD-system Quantikine ELISA
The same Mtb antigen- and PHA-stimulated samples used for
the Bio-Rad human 17-plex assay experiment 2, LINCO human
29-plex assay and RnD Systems fluorokine-(MAP) experiment 1
assay were also assessed by ELISA. The ELISA was done using the
RnD Systems IFN-c Quantikine ELISA kit (cat# DIF50)
according to the manufacturer’s instructions. Briefly, lyophilised
Quantikine standard was reconstituted in distilled water and
serially diluted one in two in kit standard diluent to produce a
seven-point standard curve ranging from 15.6 pg/ml to 1000 pg/
ml. Thereafter, 100 ml of assay diluent was added to the
designated wells in a 96-well polystyrene microplate (provided
with the kit) coated with polyclonal antibody against IFN-c,
followed immediately by 100 ml of standard, sample or control.
The standard curve, samples and controls were run in duplicate.
The plate was incubated for two hours at room temperature,
washed and thereafter 200 ml of horseradish peroxydase (HRP)-
conjugated IFN-c antibody followed by 200 ml of substrate
solution was added to the wells, followed by another incubation
period and washing step between the two additions. After
Table 1. Bio-Rad human 17-plex expected and observed
cytokine concentrations and recovery (experiment 1).
Expected
(pg/ml) High RP1 target Low RP1 target
Observed
(pg/ml)
Recovery
(%)
Observed
(pg/ml)
Recovery
(%)
IFN-gamma 1797.5 OOR. NA 9316 518.3
179.7 600.25 334 491.23 273.36
18.0 40.36 224.2 27.1 150
TNF-alpha 10351.4 8424.8 81.4 16605.5 160.4
1035.1 2212 213.7 1582.7 152.9
103.5 178.7 172.6 138.7 134.0
IL-1beta 3132.0 4082.4 130.3 10131.7 323.5
313.2 1800.33 574.8 421.8 134.7
31.3 56.6 180.7 49.4 157.7
IL-2 1762.7 1882.8 106.8 2895.7 164.3
176.3 363.8 206.4 302.2 171.4
17.6 40.3 228.7 32.6 185.0
IL-4 695.4 707.1 101.7 OOR. NA
69.5 202.8 291.6 164.7 236.8
7.0 22.2 319.2 15.3 220.0
IL-5 5159.5 8582.8 166.3 13496 261.6
516.0 2727.2 528.6 739.7 143.4
51.6 96.4 186.8 79.5 154.1
L-6 3422.8 2817 82.3 8190.6 239.3
342.3 893.2 261.0 550.6 160.9
34.2 107.9 315.3 60.4 176.5
IL-7 5460.6 9190 168.3 10819.1 198.1
546.1 1392 254.9 1032 189.0
54.6 145.1 265.8 98.6 180.6
IL-8 3672.0 3702.8 100.8 5661.5 154.2
367.2 861.3 234.6 613 166.9
36.7 89 242.4 39.1 106.5
IL-10 4810.6 4540.7 94.4 7128.86 148.2
481.1 1348.9 280.4 732.23 152.2
48.1 98.43 204.6 75.53 157.0
IL-12-p70 4798.2 4641.6 96.7 OOR. NA
479.8 1191.7 248.4 942 196.3
48.0 114 237.6 68.4 142.6
IL-13 762.5 1116.1 146.4 1401 183.7
76.3 169.7 222.6 140.1 183.7
7.6 15.7 205.8 14.1 184.8
IL-17 2765.6 3074.8 111.2 9773.8 353.4
276.6 940.6 340.1 791.9 286.3
27.7 110.2 398.4 70.6 255.2
GM-CSF 2552.7 4100.5 160.6 4716.7 184.8
255.3 597.3 234.0 478.6 187.5
25.5 55.1 215.8 42 164.5
G-CSF 2536.6 21494.94 847.4 3861 152.2
253.7 564.8 222.7 431.6 170.1
25.4 50.1 197.5 40.2 158.5
MCP-1 3412.6 5958.1 174.6 7755.5 227.3
Expected
(pg/ml) High RP1 target Low RP1 target
Observed
(pg/ml)
Recovery
(%)
Observed
(pg/ml)
Recovery
(%)
341.3 700.5 205.3 595.1 174.4
34.1 16.7 48.9 7.5 22.0
MIP-beta 2544.7 1962.6 77.1 6157.1 242.0
254.5 636.56 250.2 382.1 150.2
25.4 47.5 186.7 44.9 176.4
Unstimulated whole blood culture supernatant samples were spiked at three
different concentrations of recombinant cytokines. Samples were analysed on
the Bio-plex system instrument and the recovery of each cytokine in the panel
assessed. The expected concentrations, after subtraction of the endogenous
levels of cytokines, are represented.
doi:10.1371/journal.pone.0002535.t001
Table 1. Cont.
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wells and the plate read at 450 nm, with the wavelength correction
set at 570 nm, on a multi-detection microplate reader (Bio-Tek
instruments Inc, part # 7081000). Sample concentrations were
determined using the KC4 microplate data analysis software,
version 3.34, revision 12.
Statistics: Manufacturer 1d, 2, 3 assays and ELISA
comparison (Study 2)
The correlation between the concentrations of cytokines as
measured by the different Immunoassays for the same sample was
assessed by the mean of intra-class correlation coefficients and the
Pearson product-moment correlation coefficient. The analysis was
done using STATISTICA (version 7).
Results
Manufacturer 1 assay
Experiment 1. The recovery of the Bio-Rad human 17-plex
was assessed using spiked whole blood culture supernatants from
three healthy individuals and each of the supernatants was spiked
at three different concentrations. Generally, a lack of accuracy was
observed as illustrated in Table 1. At a high RP1 target, 21% of
positive readings were in the recovery range of 70 to 130%,
whereas only 12.4% were within that range when samples were
read at a low RP1 target.
Experiment 2. In this study, recovery of the Bio-Rad human
17-plex was assessed for five different concentrations of individual
cytokines. Fluorescence was read both at high and low RP1
targets, with 85 readings made for each RP1 target. A total of 65
readings out of 85 were positive for the low RP1 target, with 54%
of these positive readings (41.2% of the total readings) falling
within the acceptable recovery range of 70 to 130%. There were
62 positive readings out of 85 at the high RP1 target, with 61% of
these (44.7% of the total readings) falling within the acceptable
recovery range of 70 to 130%. The cytokines IFN-c, TNF-a, IL-
1b, IL-2, IL-4, IL-6, IL-7, IL-12p70, IL-13, IL-17, GM-CSF and
MCP-1 measured most accurately when samples were read at the
high RP1 target, whereas measurements of IL-5, IL-10, G-CSF
and MIP-1b showed better recoveries when samples were read at a
low RP1 target. Interfering interactions in the samples presumably
led to falsely increased and signal inhibition for IL-8 detection,
which resulted in out-of-range readings for four out of the five
assessed concentrations.
The recoveries of cytokines included in the Bio-Rad human 17-
plex panel are shown in Figure 1 (recoveries from two independent
experiments). Detailed statistics on Bio-Rad human 17-plex
recovery and variations are shown in Table 2.
Manufacturer 2 assay
Experiment 1. The recovery of the cytokines forming part of
the LINCO-Inc 29-plex panel were assessed at five different
concentrations (5 000, 1 000, 500, 50 and 10 pg/ml), and read at
high and low RP1 targets. The test showed an acceptable
performance. A total of 145 readings were made at each RP1
target and 123 of these fell within the detection range when read at
high RP1, compared to 136 out of 145 when read at the low RP1
target. Of the positive readings, 78.4% (66.2% of the total
Figure 1. Recoveries of the Bio-Rad 17-plex assay. Un-stimulated whole blood culture supernatant samples from healthy donors were spiked
at three (experiment 1) and five (experiment 2) different concentrations (2–8062 pg/ml) with the standard from the Bio-Rad 17-plex kit. Samples were
assayed in duplicate and read at high and low RP1 targets on the Bio-plex system instrument. Recoveries were calculated for each of the cytokines in
the panels for each of the spiked concentrations. The figure shows the recoveries obtained for each individual cytokine after two independent
experiments.
doi:10.1371/journal.pone.0002535.g001
Luminex Immunoassays
PLoS ONE | www.plosone.org 4 July 2008 | Volume 3 | Issue 7 | e2535Figure 2. Recoveries of the Linco 29-plex assay. Un-stimulated whole blood culture supernatant samples from healthy donors were spiked at
five (experiment 1) and two (experiment 2) different concentrations ranging from 10–5000 pg/ml with the standards from the LINCO 29-plex kit.
Samples were assayed in duplicate and read at high and low RP1 targets on the Bio-plex system instrument. Recoveries were calculated for each of
the cytokines in the panels for each of the spiked concentrations. The figure shows the recoveries obtained for each individual cytokine after two
independent experiments.
doi:10.1371/journal.pone.0002535.g002
Table 2. Detailed statistics of Bio-Rad 17-plex assay recoveries (two independent experiments).
Cytokines IFN-g TNF-a IL-1b IL-2 IL-4 IL-5 IL-6 IL-7 IL-8
Number of positive reads 14 13 13 13 13 13 13 13 10
Minimum 20.3 51.47 23.77 88.89 43.07 14.7 19.63 67.52 100.2
Median 98.37 91.43 114.5 106.3 101.7 115.7 92.05 168.3 104
Maximum 518.3 152.9 323.5 692.5 319.2 261.6 176.5 824 166.9
Mean 165.2 100.2 138.4 203.8 147 126.4 101.1 225 118.8
Std. Deviation 160.8 36.1 91.58 219.2 110.6 77.82 54.27 269.7 32.21
Std. Error 56.84 13.64 34.61 82.85 41.8 27.51 20.51 101.9 16.11
Coefficient of variation 97.32% 36.03% 66.15% 107.55% 75.22% 61.56% 53.67% 119.86% 27.13%
Cytokines IL-10 IL-12p70 IL-13 IL-17 MCP1 MIP-1b G-CSF GM-CSF
Number of positive reads 14 14 13 13 12 12 13 13
Minimum 17.69 17.47 83.66 63.5 48.9 61.9 26.49 83.32
Median 86.81 96.84 146.4 111.2 69.05 93.07 105.5 160.6
Maximum 194.4 230.3 259.1 554.4 174.6 176.4 170.1 850.1
Mean 102.1 117.3 150.5 204.3 99.58 108.6 114.3 232.1
Std. Deviation 60.77 69.12 63.35 178.7 58.53 44.71 50.41 275.8
Std. Error 21.49 24.44 23.95 67.52 23.89 18.25 19.05 104.3
Coefficient of variation 59.50% 58.91% 42.09% 87.46% 58.77% 41.16% 44.11% 118.82%
Unstimulated whole blood culture supernatant samples were spiked at different concentrations with recombinant cytokines. Samples were analysed on the Bio-plex
system instrument and the recovery of each cytokine in assessed after subtraction of the endogenous levels of cytokines.
doi:10.1371/journal.pone.0002535.t002
Luminex Immunoassays
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the acceptable range of 70 to 130%, whereas approximately 70%
of positive readings (65.7% of the total readings) made at a low
RP1 target achieved this acceptable recovery. Measurements of
IFN-c, IL-1b, IL-4, IL-6, IL-7, IP-10, MCP-1 and G-CSF were
found to be most accurate when the plate was read at a high RP1
target, with recoveries falling between 70 to 130%, whereas those
for TNF-a, IL-1a, IL-1ra, IL-2, IL-5, IL-10, IL-12p40, IL-12p70,
IL-13, Fractalkine, MIP-1a, MIP-1b, GM-CSF, TGF-a, sCD40L,
VEGF, Eotaxine and EGF were most accurate when read at a low
RP1 target. IL-15 and IL-17 showed similar recoveries at both
high and low RP1 targets. The level of background signal was very
high for IL-8; this was most probably due to de fact that whole
blood supernatant used for the spiking experiment was not pre-
diluted. The coefficients of variation between the measurement at
high RP1 and low RP1 targets were less than 5% when applicable
(when both high and low RP1 showed positive readings).
Experiment 2. The assessment of LINCO -plex kit was
repeated only this time 21 cytokine were assessed. The repeat
experiment was done using a healthy donor whole blood
supernatant spiked at two different concentrations. The
recoveries of all the cytokines in panel fell within the acceptable
Table 3. Detailed statistics of Linco-plex assay recoveries (two independent experiments).
Cytokines IL-1a IL-1b IL-1ra (2) IL-2 IL-4 IL-5 IL-6 IL-7
Number of positive reads 6 7 4 7 7 7 5 7
Minimum 61.44 70.7 35.02 77.09 70.92 75.23 55.12 64.04
Median 87.88 93.63 82.98 87.9 92.48 112.8 78.96 77.5
Maximum 99.01 123.2 180.5 102.9 314.4 177 110.2 120.9
Mean 85.43 94.49 95.37 87.58 121.1 118.6 81.48 84.32
Std. Deviation 12.92 18.51 61.23 8.522 86.17 34.65 22.5 19.67
Std. Error 5.275 6.997 30.62 3.221 32.57 13.09 10.06 7.433
Coefficient of variation 15.13% 19.59% 64.21% 9.73% 71.15% 29.22% 27.62% 23.32%
Cytokines IL-8 IL-10 IL-12p40 (2) IL-12p70 IL-13 IL-15 IL-17 IFN-g
Number of positive reads 4 7 4 7 7 7 7 7
Minimum 76.67 52.7 67.87 91 30.2 77.64 78.64 80.07
Median 108.1 77.15 68.75 97.1 78.02 85.7 90.58 90.29
Maximum 233 86.8 71 304.3 95.84 128.3 134.9 128.2
Mean 131.5 74.81 69.09 131.8 74.22 96.48 94.31 95.23
Std. Deviation 69.34 10.69 1.371 77.84 20.59 20.33 19.22 17.9
Std. Error 34.67 4.039 0.6857 29.42 7.781 7.685 7.264 6.767
Coefficient of variation 52.74% 14.28% 1.98% 59.08% 27.74% 21.07% 20.38% 18.80%
Cytokines TNF-a MCP1 G-CSF GM-CSF MIP-1a MIP-1b (2) IP-10 TGF-a (2)
Number of positive reads 7 6 5 7 5 4 7 5
Minimum 61.6 70.88 46.55 81.44 53.06 59.3 22.3 90.15
Median 76.02 135.3 74.83 87.1 69.19 78.55 95.25 99.96
Maximum 139.2 251.5 92.58 100.1 109.5 93.94 218.3 121.4
Mean 84.19 148.7 71.77 87.84 76.99 77.58 96.86 105.3
Std. Deviation 25.56 60.57 17.57 6.146 21.91 14.22 61.94 12.94
Std. Error 9.659 24.73 7.856 2.323 9.8 7.109 23.41 5.785
Coefficient of variation 30.35% 40.73% 24.47% 7.00% 28.46% 18.33% 63.94% 12.28%
Cytokines Fractalkine (2) sCD40L (2) VEGF (2) EGF (2) Eotaxin
Number of positive reads 5 5 4 5 7
Minimum 66.46 76.8 65.1 81.6 17.3
Median 76.12 79.4 102.4 86.58 80.17
Maximum 128.2 90.38 108.3 97.24 86.1
Mean 90.79 81 94.53 87.18 69.37
Std. Deviation 26.22 5.407 19.82 6.149 23.74
Std. Error 11.72 2.418 9.911 2.75 8.973
Coefficient of variation 28.88% 6.67% 20.97% 7.05% 34.23%
(2) Cytokines not included in the second test.
Unstimulated whole blood culture supernatant samples were spiked at different concentrations with recombinant cytokines. Samples were analysed on the Bio-plex
system instrument and the recovery of each cytokine assessed after subtraction of the endogenous levels of cytokines.
doi:10.1371/journal.pone.0002535.t003
Luminex Immunoassays
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recoveries were 66 and 251% respectively. Figure 2 shows the
recoveries of the LINCO -plex assay after the 2 independent
experiments. Detail statistics are shown in Table 3.
The reproducibility of the LINCO kits was done by measuring
cytokine concentrations of the same whole blood supernatants across
five LINCO 29-plex kits. Data analysis showed that the coefficient of
variation, standarddeviation and error were within acceptableranges
for most of the cytokines (see Table 4 for more details).
Manufacturer 3 assay
Experiment 1. The recoveries of 13 cytokines measured in
whole blood culture supernatant and serum samples were assessed
for six different concentrations using the RnD Systems Fluorokine-
MAP assay. A total of 78 readings were made using whole blood
culture supernatant and 67 from serum samples. All whole blood
supernatant and serum sample readings were positive and within
the standard curve range. A total of 67% of whole blood
supernatant samples achieved recoveries within 70 to 130%,
compared to approximately 56% of the serum samples.
Experiment2. The recoveries ofIFN-c,TNF-a and IL-4were
assessed for seven different concentrations in whole blood culture
supernatant and serum samples. In this experiment all whole blood
supernatant readings were positive, whereas the detection limits in
spiked serum samples were 44 pg/ml. About 50% of spiked whole
blood supernatant achieved acceptable recovery (70 to 130%)
Table 4. Linco 29-plex assay reproducibility.
Cytokines IL-1B IL-2 IL-1ra IL-4 IL-5 EGF IL-6 IL-7 TGF2a
Number of experiments 5 5 5 5 5 5 5 5 5
Minimum concentration 6.46 1.6 52.92 5.8 6.05 1.6 238.7 3.53 1.6
Median concentration 7.27 1.6 59.7 9.36 6.87 1.6 258.8 3.99 1.6
Maximum concentration 9.17 4.33 79.18 14.09 8.55 1.6 304.9 8.69 1.6
Mean concentration 7.378 2.538 65.58 10.29 7.038 1.6 261.6 5.182 1.6
Std. Deviation 1.099 1.313 12.37 3.294 0.9504 0 26.13 2.19 0
Std. Error 0.4914 0.5872 5.533 1.473 0.425 0 11.69 0.9794 0
Coefficient of variation 14.89% 51.73% 18.87% 32.01% 13.50% 0.00% 9.99% 42.26% 0.00%
Cytokines Fractalkine IL-8 IL-10 IL-12p70 IL-13 IL-15 IL-17 IL-1a IFN-c
Number of experiments 5 5 5 5 5 5 5 5 5
Minimum concentration 1.6 828.4 143.1 1.6 18.9 1.6 12.34 22.73 687.4
Median concentration 1.6 960.2 161.8 1.6 20.15 1.6 13.86 24.16 801.5
Maximum concentration 43.48 1153 200.4 4.71 26.7 1.6 20.83 32.38 993.7
Mean concentration 11.31 969.8 167.9 2.222 21.17 1.6 14.96 25.65 807.1
Std. Deviation 18.21 116.9 21.57 1.391 3.238 0 3.351 3.851 127.1
Std. Error 8.145 52.29 9.648 0.622 1.448 0 1.499 1.722 56.85
Coefficient of variation 161.01% 12.06% 12.85% 62.59% 15.29% 0.00% 22.41% 15.01% 15.75%
Cytokines G-CSF GM-CSF TNF2a Eotaxin MCP-1 sCD40L IL-12p40 MIP-1a MIP-1b
Number of experiments 5 5 5 4 5 5 5 5 5
Minimum concentration 22.19 52.82 33.06 2.52 430.2 9 10.2 604.5 466.3
Median concentration 30.91 58.65 36.34 7.965 520.4 10.05 22.11 665.6 516.1
Maximum concentration 34.29 70.71 49.75 18.78 559 18.53 38.45 777.7 623.4
Mean concentration 29.65 59.71 38.3 9.308 502.6 12.85 21.96 690.1 519.2
Std. Deviation 4.656 6.728 6.618 7.101 50.63 4.788 10.45 75.02 64.1
Std. Error 2.082 3.009 2.96 3.55 22.64 2.141 4.674 33.55 28.67
Coefficient of variation 15.70% 11.27% 17.28% 76.29% 10.07% 37.26% 47.58% 10.87% 12.35%
Cytokine IP-10 VEGF
Number of experiments 5 5
Minimum concentration 140 30.58
Median concentration 159.1 52.07
Maximum concentration 287.8 64.79
Mean concentration 182.1 50.43
Std. Deviation 60.02 13.84
Std. Error 26.84 6.189
Coefficient of variation 32.96% 27.44%
Five aliquots of the same PHA-stimulated whole blood supernatant were produced and each aliquot was run on different plates and on different days.
doi:10.1371/journal.pone.0002535.t004
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range. Details on cytokine recoveries after the two independent
experiments are shown in Figure 3 detailed statistics in Table 5.
RnD System’s ELISA
The RnD System’s IFN-c ELISA was used as a comparative test
against which the different luminex kits where compared. Samples
tested included antigen-stimulated samples with their negative and
positive controls. As expected, the negative control showed a very
low level of IFN-c, whereas the positive control and antigen-
stimulated samples showed higher levels of IFN- c (Table 6).
Manufacturer 1, 2, 3 luminex assays and RnD Systems
ELISA: an IFN-c based comparison
Poor correlations were observed between the Bio-Rad luminex
assay and the other assays. The correlation between the Bio-Rad
luminex kit and the RnD Systems ELISA measurement gave an
ICC of agreement of 20.01 and a Pearson correlation coefficient
(r) of 20.09. The intra-class correlation coefficients (ICC) of
agreement and the Pearson product-moment correlation coeffi-
cient (r) between LINCO luminex kits and RnD Systems ELISA
kits were for the first test 0.64 (ICC) and 0.75 (r) and for the
second test 0.75 and (ICC) and 0.84 (r) suggesting a posive
Figure 3. Recoveries of RnD System’s Fluorokine-MAP 13-plex base kits A and B. (A) Un-stimulated whole blood culture supernatant
samples from a healthy donor were spiked at different concentrations (14–19000 pg/ml) with the standards from RnD-System Fluorokine-MAP base
kits A and B. Samples were assayed in duplicate, read at a low RP1 target on the Bio-plex system instrument and recoveries calculated for each of the
cytokines in the panel. The figure shows the individual cytokine’s best recovery obtained. (B) Serum samples from a healthy donor were spiked at
concentrations (43.8–19000 pg/ml) with the standards from RnD-System’s Fluorokine-MAP base kits A and B. Samples were assayed in duplicate, read
at a low RP1 target on the Bio-plex system instrument and recoveries calculated for each of the cytokines in the panel. The figure shows the
individual cytokine’s recoveries obtained. The experiment was repeated for IFN-c, TNF-a and IL-4 only.
doi:10.1371/journal.pone.0002535.g003
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correlation analysis between RnD Systems Fluorokine-MAP and
RnD Systems ELISA was also shown to be positive with an ICC
of agreement of 0.1 and a Pearson correlation coefficient (r) of
0.99. The correlation between the different luminex kits
measurements for the cytokines present in the three kit panels
is shown in Table 7.
Discussion
This validation study evaluated three commercially available
cytokine multiplex bead immunoassays from Bio-Rad, LINCO-
Inc and RnD Systems. The results suggest that, for the particular
samples tested in this study, the LINCO Inc human 29-plex and
the RnD Systems Fluorokine-MAP assays were the most accurate
Table 5. RnD System’s Fluorokine-MAP kits assay recoveries detailed statistics (two independent experiments).
Whole blood Supernatant
Cytokines IFN-c (*) TNF-a (*) IL-1a IL-1ra IL-4 (*) IL-6 IL-8 IL-10
Number of positive reads 13 13 6 6 13 6 6 6
Minimum 22.73 22.73 82.99 47.73 63.66 88.34 25.6 84.6
Median 57.55 76.71 90.76 77.52 81.01 96.28 74.01 87.68
Maximum 94.36 94.36 104.9 86.32 121.8 109.2 92.93 93.5
Mean 54.86 63.31 91.64 73.72 86.62 97.41 68.23 88.75
Std. Deviation 21.9 25.14 7.599 14.38 17.7 7.541 22.86 3.453
Std. Error 6.074 6.974 3.102 5.87 4.909 3.079 9.333 1.41
Coefficient of variation 39.92% 39.72% 8.29% 19.50% 20.43% 7.74% 33.51% 3.89%
Cytokines IL-12p70 MCP1 MIP-1a MIP-1b IP-10
Number of positive reads 6 6 6 6 6
Minimum 122.1 59.9 60.69 59.57 60.14
Median 179.4 82.48 63.92 98.28 88.24
Maximum 280.2 90.39 71.71 148 93.05
Mean 182.6 77.91 64.67 102.4 80.71
Std. Deviation 56.27 11.38 4.02 32.9 14.74
Std. Error 22.97 4.645 1.641 13.43 6.019
Coefficient of variation 30.81% 14.60% 6.22% 32.12% 18.27%
Serum
Cytokines IFN-c (*) TNF-a (*) IL-1a IL-1ra IL-4 (*) IL-6 IL-8 IL-10
Number of positive reads 10 9 5 5 9 5 5 5
Minimum 29.33 47.49 56.34 52.55 68.86 46.58 47.59 51.28
Median 62.64 75.86 74.51 76.46 95.91 71.15 78.61 76.97
Maximum 95.91 133 84.16 86.62 135.3 72.72 88.71 88.34
Mean 61.04 87.51 72.65 72.07 101.2 63.83 73.62 73.63
Std. Deviation 23.87 31.61 12.18 13.13 25.39 11.53 16.08 13.68
Std. Error 7.549 10.54 5.447 5.87 8.462 5.155 7.192 6.116
Coefficient of variation 39.11% 36.12% 16.77% 18.21% 25.08% 18.06% 21.84% 18.57%
Cytokines IL-12p70 MCP1 MIP-1a MIP-1b IP-10
Number of positive reads 6 5 5 5 6
Minimum 46.58 43.56 33.23 64.53 18.04
Median 71.3 73.44 55.49 104.2 20.51
Maximum 94.84 87.65 61.87 130 28.8
Mean 69 70.12 50.66 99.63 22.02
Std. Deviation 16.33 16.17 12.62 23.74 4.018
Std. Error 6.665 7.231 5.645 10.62 1.641
Coefficient of variation 23.66% 23.06% 24.92% 23.83% 18.25%
(*) Cytokines included in both experiment 1 and 2.
Unstimulated whole blood culture supernatant and serum samples were spiked at different concentrations with recombinant cytokines. After samples were measured
and the level endogenous levels of cytokines subtracted the recovery of each cytokine was assessed. Only IFN-c, TNF-a and IL-4 were included in the second
experiment.
doi:10.1371/journal.pone.0002535.t005
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culture supernatant and achieved good recovery ranges and
reproducibility for most cytokines whereas the performance of the
Bio-Rad human 17-plex assay was suboptimal.
The comparative study, including the Bio-Rad human 17-plex
assay, LINCO 29-plex assay, RnD Systems Fluorokine-MAP assay
and RnD Systems ELISA, was made based on IFN-c responses in
antigen-stimulated whole blood culture supernatant. It was found
that all assays were capable of differentiating the positive and
negative controls. Moreover, they were able to efficiently pick up
the antigen-specific IFN-c responses when applicable, with the
exception of the Bio-Rad human 17-plex assay, where IFN-c levels
in two of the antigen-stimulated samples (ESAT-CFP-10 and
Rv1115) went undetected.
Concentrations of IFN-c measured by the LINCO 29-plex assay,
RnD Systems Fluorokine-MAP assay and ELISA correlated, but
results obtained using the Bio-plex assay correlated poorly with
values obtained using the other three assays. Very similar to the
findings by DuPont et al. [5], a very strong correlation between the
level of IFN-c measured by ELISA and the LINCO-plex kit in
whole blood culture supernatant was found in the present study.
Furthermore LINCO-plex assay, RnD Systems Fluorokine-MAP
assay and the Bio-Rad 17-plex correlation of 13 cytokines showed a
positive correlation between LINCO 29-plex and the RnD Systems
Fluorokine-MAP assay for most of the cytokines, whereas the Bio-
Rad 17-plex assay correlations to LINCO 29-plex assay and the
RnDSystemsFluorokine-MAPassaywerefrequentlynegative.This
contradicts a study by Khan et al. [11], who showed that cytokine
levels of IL-6, IL-8, and TFN-a measured by the Bio-Rad Bio-plex
assay have similar trends to the LINCO-plex and RnD Systems
Fluorokine-MAP measurements at least for IL-6, IL-8, and TFN-a.
Although recoveries should ideally not fall outside the acceptable
range, measurements may be considered useable if the recovery
remains constant across different sample types and dilutions. This
wasnot the case when measuring cytokinesusingthe Bio-Radkits in
our study. Therefore it would be impossible to compensate for any
inaccuracy evident in any one sample matrix. Discrepancies
observed using the Bio-plex kits may be partly explained by the
presence of interfering proteins such as heterophilic antibodies
[10,14]. De Jager et al. [3] have described methods to avoid
heterophilic antibody interference in plasma and synovial fluid that
improved the performance of the multiplex immunoassay. Howev-
er, any manipulation of samples in clinical studies is not necessarily
advantageous due to possible unforeseen effects on the results.
It maythereforebe necessaryto perform careful optimisationand
validation of any commercial multiplex cytokine assays prior to
large-scale clinical studies, as the quality controls supplied with the
kits to measure standard curve integrity can only guarantee the
accuracy or sensitivity of the assay if they are reconstituted and
measured in the same matrix type as the samples investigated.
Matrix effects appear to play a major role in assay performance and
the type of sample tested may therefore have serious effects on assay
performance. It is clear that, at the present moment, the theoretical
capabilities of this new technology cannot be fully achieved in
practice [12]. Researchers using these kits should include replicates
of samples as well as negative and positive (low, medium and high)
controls with known concentrations of the cytokines of interest to
aid in them in interpretation of results. Furthermore, controls
should be included that reflect both the diluents used to reconstitute
the standard supplied with the kit and the sample matrix tested in
order to account for possible matrix effects. This will allow the
assessment of linearity and recovery and aid in the choice of best
standard curve regression and optimal calibration [2].
In conclusion, the most appropriate use for multiplex cytokine
assays based on luminex technology currently is as a screening
tool, for example for the selection of candidate markers
characteristic of disease-associated immune responses. Promising
candidates can then be validated using a method with higher
accuracy and proven reliability, such as ELISA.
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Table 6. IFN-c-based comparison of ELISA, LINCO 29-plex, Bio-Rad 17-plex and RnD Systems Fluorokine-MAP-13-plex assays.
RnD Systems
ELISA (pg/ml)
LINCO 29-plex
(pg/ml)
Bio-Rad
17-plex (pg/ml)
RnD Systems
Fluorokine-MAP (pg/ml)
Whole blood supernatant
PHA-stimulated 1731.38 451.56 64.7 86.83
Negative Control 0 1.39 0 NA
Mtb derived antigen 1 (supernatant A) 1181.6 969.12 0 NA
Mtb derived antigen 1 (supernatant B) 908.83 950.62 2.14 NA
Mtb derived antigen 2 (supernatant B) 839.42 536.92 193.53 NA
Mtb derived antigen 3 (supernatant D) 489.1 247 49.08 30.26
Mtb derived antigen 2 (supernatant C) 235.67 125.97 104.94 17.65
Mtb derived antigen 4 (supernatant E) 118.9 133.82 172.19 NA
Mtb derived antigen 3 (supernatant C) 57.5 55.63 0 1.56
Mtb derived antigen 5 (supernatant E) 23.78 0.44 99.2 0.28
NA: Not applicable because the sample was not measured with the RnD Systems Fluorokine-MAP base kit A
Supernatant was generated using whole blood from a healthy donor (A-E) in six day assays stimulated with 5 differents Mtb derived antigens and with
phytohaemagglutinin (PHA). The LINCO 29-plex measurement most closely resembled that of the RnD Systems ELISA in absolute value, and followed a similar trend, but
absolute values for all three luminex assay fell below that of the ELISA.
doi:10.1371/journal.pone.0002535.t006
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